Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 256.53
NLNK's Cash to Debt is ranked higher than
53% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 59.90 vs. NLNK: 256.53 )
Ranked among companies with meaningful Cash to Debt only.
NLNK' s Cash to Debt Range Over the Past 10 Years
Min: 0.79  Med: 49.17 Max: N/A
Current: 256.53
Equity to Asset 0.74
NLNK's Equity to Asset is ranked higher than
58% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NLNK: 0.74 )
Ranked among companies with meaningful Equity to Asset only.
NLNK' s Equity to Asset Range Over the Past 10 Years
Min: -5.11  Med: 0.81 Max: 0.93
Current: 0.74
-5.11
0.93
F-Score: 2
Z-Score: 3.85
M-Score: 1.38
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -298.25
NLNK's Operating margin (%) is ranked lower than
63% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -88.13 vs. NLNK: -298.25 )
Ranked among companies with meaningful Operating margin (%) only.
NLNK' s Operating margin (%) Range Over the Past 10 Years
Min: -2849.13  Med: -1036.44 Max: 68.12
Current: -298.25
-2849.13
68.12
Net-margin (%) -303.49
NLNK's Net-margin (%) is ranked lower than
64% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. NLNK: -303.49 )
Ranked among companies with meaningful Net-margin (%) only.
NLNK' s Net-margin (%) Range Over the Past 10 Years
Min: -2852.7  Med: -1017.04 Max: 55.63
Current: -303.49
-2852.7
55.63
ROE (%) -53.72
NLNK's ROE (%) is ranked lower than
63% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: -34.32 vs. NLNK: -53.72 )
Ranked among companies with meaningful ROE (%) only.
NLNK' s ROE (%) Range Over the Past 10 Years
Min: -85.27  Med: -51.18 Max: 75.23
Current: -53.72
-85.27
75.23
ROA (%) -46.10
NLNK's ROA (%) is ranked lower than
63% of the 972 Companies
in the Global Biotechnology industry.

( Industry Median: -30.23 vs. NLNK: -46.10 )
Ranked among companies with meaningful ROA (%) only.
NLNK' s ROA (%) Range Over the Past 10 Years
Min: -86.63  Med: -59.98 Max: 63.63
Current: -46.1
-86.63
63.63
ROC (Joel Greenblatt) (%) -838.29
NLNK's ROC (Joel Greenblatt) (%) is ranked lower than
59% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. NLNK: -838.29 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NLNK' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -838.29  Med: -369.45 Max: 1042.38
Current: -838.29
-838.29
1042.38
Revenue Growth (3Y)(%) 209.30
NLNK's Revenue Growth (3Y)(%) is ranked higher than
98% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. NLNK: 209.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NLNK' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -33.8 Max: 209.3
Current: 209.3
0
209.3
EBITDA Growth (3Y)(%) 1.10
NLNK's EBITDA Growth (3Y)(%) is ranked lower than
51% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. NLNK: 1.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NLNK' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0.55 Max: 1.9
Current: 1.1
0
1.9
EPS Growth (3Y)(%) 8.00
NLNK's EPS Growth (3Y)(%) is ranked higher than
64% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: -3.10 vs. NLNK: 8.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NLNK' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 1.15 Max: 8
Current: 8
0
8
GuruFocus has detected 4 Warning Signs with NewLink Genetics Corp $NLNK.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NLNK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

NLNK Guru Trades in Q1 2016

Jim Simons 726,700 sh (+1176.68%)
Paul Tudor Jones 18,000 sh (+185.71%)
First Eagle Investment 9,072 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 138,300 sh (unchged)
First Eagle Investment 1,754,700 sh (-2.15%)
» More
Q2 2016

NLNK Guru Trades in Q2 2016

Paul Tudor Jones 35,400 sh (+96.67%)
First Eagle Investment 2,186,700 sh (+24.62%)
Jim Simons 815,500 sh (+12.22%)
First Eagle Investment 5,913 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund Sold Out
» More
Q3 2016

NLNK Guru Trades in Q3 2016

First Eagle Investment 5,713 sh (unchged)
First Eagle Investment 2,186,700 sh (unchged)
Paul Tudor Jones Sold Out
Jim Simons 346,800 sh (-57.47%)
» More
Q4 2016

NLNK Guru Trades in Q4 2016

First Eagle Investment 5,713 sh (unchged)
First Eagle Investment 2,129,200 sh (-2.63%)
Jim Simons 145,800 sh (-57.96%)
» More
» Details

Insider Trades

Latest Guru Trades with NLNK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:CERS, NAS:ATRA, NAS:CYTK, OTCPK:CNBX, NAS:RGNX, NAS:CTMX, NAS:NK, OTCPK:ABVC, NAS:OTIC, NAS:OMER, OTCPK:MEOBF, NAS:SPPI, NAS:NVAX, NAS:PTI, NAS:BCRX, NAS:MACK, NAS:PTCT, NAS:AVDL, NAS:CARA, NAS:NTLA » details
Traded in other countries:4NX.Germany,
NewLink Genetics Corp is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing immunotherapeutic products to improve treatment options for patients with cancer.

NewLink Genetics Corp., was incorporated in Delaware on June 4, 1999. The Company is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. Its products include biologic and small-molecule immunotherapy product candidates intended to treat oncology indications. Its product candidate, HyperAcute Pancreas cancer immunotherapy, or HyperAcute Pancreas, is being studied in a Phase 3 clinical trial in surgically-resected pancreatic cancer patients that is being performed under a Special Protocol Assessment, or SPA, with the United States Food and Drug Administration, or FDA. The Company initiated this trial based on encouraging interim Phase 2 data that suggests improvement in both disease-free and overall survival. The Company has also received Fast Track and Orphan Drug designations from the FDA for this product candidate for the adjuvant treatment of surgically-resected pancreatic cancer. It has three additional product candidates in clinical development, including its HyperAcute Lung cancer immunotherapy, or HyperAcute Lung, which is being studied in a Phase 1/2 clinical trial at the National Cancer Institute, or NCI, and its HyperAcute Melanoma cancer immunotherapy, or HyperAcute Melanoma, which is being studied in an investigator-initiated Phase 2 clinical trial. To date, its HyperAcute product candidates have been dosed in more than 200 cancer patients either as a monotherapy or in combination with other therapies and have demonstrated a favorable safety profile. Its HyperAcute product candidates are based on its proprietary HyperAcute immunotherapy technology, which is designed to stimulate the human immune system. Its HyperAcute product candidates use allogeneic (non-patient specific) cells from previously established cell lines rather than cells derived from the patient. The Company thinks its approach enables a simpler, consistent and scalable manufacturing process than therapies based on patient specific tissues or cells. It discovers, develops and commercializes immunotherapeutic products for the treatment of cancer where the needs of patients are unmet by current therapies. The Company faces competition from other public and private biopharmaceutical companies, public and private universities and research organizations actively engaged in the discovery and research and development of products for cancer. The Company is subject to federal, state, local and foreign regulation.

Ratios

vs
industry
vs
history
P/B 3.21
NLNK's P/B is ranked higher than
56% of the 1106 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. NLNK: 3.21 )
Ranked among companies with meaningful P/B only.
NLNK' s P/B Range Over the Past 10 Years
Min: 1.63  Med: 6.54 Max: 21.18
Current: 3.21
1.63
21.18
P/S 14.34
NLNK's P/S is ranked lower than
54% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: 12.50 vs. NLNK: 14.34 )
Ranked among companies with meaningful P/S only.
NLNK' s P/S Range Over the Past 10 Years
Min: 4.56  Med: 81.67 Max: 1056.82
Current: 14.34
4.56
1056.82
EV-to-EBIT -3.25
NLNK's EV-to-EBIT is ranked lower than
99.99% of the 284 Companies
in the Global Biotechnology industry.

( Industry Median: 19.01 vs. NLNK: -3.25 )
Ranked among companies with meaningful EV-to-EBIT only.
NLNK' s EV-to-EBIT Range Over the Past 10 Years
Min: -36  Med: -9.8 Max: 11.2
Current: -3.25
-36
11.2
EV-to-EBITDA -3.48
NLNK's EV-to-EBITDA is ranked lower than
99.99% of the 307 Companies
in the Global Biotechnology industry.

( Industry Median: 19.22 vs. NLNK: -3.48 )
Ranked among companies with meaningful EV-to-EBITDA only.
NLNK' s EV-to-EBITDA Range Over the Past 10 Years
Min: -37  Med: -10.1 Max: 11.1
Current: -3.48
-37
11.1
Current Ratio 4.41
NLNK's Current Ratio is ranked higher than
52% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. NLNK: 4.41 )
Ranked among companies with meaningful Current Ratio only.
NLNK' s Current Ratio Range Over the Past 10 Years
Min: 0.97  Med: 10.88 Max: 25.95
Current: 4.41
0.97
25.95
Quick Ratio 4.41
NLNK's Quick Ratio is ranked higher than
54% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 3.91 vs. NLNK: 4.41 )
Ranked among companies with meaningful Quick Ratio only.
NLNK' s Quick Ratio Range Over the Past 10 Years
Min: 0.97  Med: 10.88 Max: 25.95
Current: 4.41
0.97
25.95
Days Sales Outstanding 239.93
NLNK's Days Sales Outstanding is ranked lower than
92% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. NLNK: 239.93 )
Ranked among companies with meaningful Days Sales Outstanding only.
NLNK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 26.42  Med: 153.75 Max: 617.06
Current: 239.93
26.42
617.06

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -11.10
NLNK's 3-Year Average Share Buyback Ratio is ranked lower than
51% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. NLNK: -11.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NLNK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -23.6  Med: -10.8 Max: 0
Current: -11.1
-23.6
0

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.44
NLNK's Price/Net Cash is ranked higher than
61% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: 5.89 vs. NLNK: 4.44 )
Ranked among companies with meaningful Price/Net Cash only.
NLNK' s Price/Net Cash Range Over the Past 10 Years
Min: 2.5  Med: 8.51 Max: 29.76
Current: 4.44
2.5
29.76
Price/Net Current Asset Value 3.39
NLNK's Price/Net Current Asset Value is ranked higher than
71% of the 879 Companies
in the Global Biotechnology industry.

( Industry Median: 5.57 vs. NLNK: 3.39 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NLNK' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.3  Med: 7.01 Max: 21.93
Current: 3.39
2.3
21.93
Price/Tangible Book 3.21
NLNK's Price/Tangible Book is ranked higher than
63% of the 1015 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. NLNK: 3.21 )
Ranked among companies with meaningful Price/Tangible Book only.
NLNK' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.18  Med: 6.22 Max: 14.64
Current: 3.21
2.18
14.64
Price/Projected FCF 26.33
NLNK's Price/Projected FCF is ranked lower than
89% of the 174 Companies
in the Global Biotechnology industry.

( Industry Median: 3.31 vs. NLNK: 26.33 )
Ranked among companies with meaningful Price/Projected FCF only.
NLNK' s Price/Projected FCF Range Over the Past 10 Years
Min: 4.38  Med: 6.13 Max: 26.33
Current: 26.33
4.38
26.33
Price/Median PS Value 0.18
NLNK's Price/Median PS Value is ranked higher than
95% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. NLNK: 0.18 )
Ranked among companies with meaningful Price/Median PS Value only.
NLNK' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.06  Med: 1.16 Max: 8
Current: 0.18
0.06
8
Earnings Yield (Greenblatt) (%) -30.80
NLNK's Earnings Yield (Greenblatt) (%) is ranked lower than
79% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. NLNK: -30.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NLNK' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -30.8  Med: 11.6 Max: 16.7
Current: -30.8
-30.8
16.7

More Statistics

Revenue (TTM) (Mil) $30.72
EPS (TTM) $ -3.23
Beta2.47
Short Percentage of Float10.74%
52-Week Range $9.23 - 24.10
Shares Outstanding (Mil)29.13

Analyst Estimate

Dec16
Revenue (Mil $)
EPS ($) -2.91
EPS w/o NRI ($) -2.91
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NLNK

Headlines

Articles On GuruFocus.com
First Eagle Investment Adds to Stake in NewLink Genetics Feb 03 2016 
These Companies Show High Profit and Low Debt Jun 17 2015 
When A Stock Doubles, Don’t Trim It Automatically May 27 2015 
Greenblatt's Top Buys During First Quarter May 22 2015 
NewLink Genetics Corporation Offers a Risky Way to Generate Income Sep 11 2013 
Weekly CEO Sells Highlight: Universal Insurance Holdings Inc, Avanir Pharmaceuticals Inc, Bel Fuse I Jun 30 2012 

More From Other Websites
NewLink Genetics to Host Its Fourth Quarter and Year End 2016 Financial Results Conference Call on... Feb 20 2017
[$$] Cevec Pharma, NewLink Genetics Target Zika Through Licensing Deal Feb 13 2017
NewLink Genetics to Participate in 2017 SunTrust Orphan Drug Day on February 14th Feb 13 2017
Will NewLink Genetics (NLNK) Continue to Surge Higher? Feb 10 2017
Lifshitz & Miller Law Firm Announces Investigation of DaVita Inc., First NBC Bank Holdings Company,... Jan 18 2017
NewLink Genetics Corp. – Value Analysis (NASDAQ:NLNK) : January 11, 2017 Jan 11 2017
NewLink Genetics Corp. breached its 50 day moving average in a Bullish Manner : NLNK-US : January... Jan 10 2017
Newman Ferrara LLP Announces Corporate Governance Investigation of NewLink Genetics Corporation Jan 09 2017
NEWLINK GENETICS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Jan 05 2017
ETFs with exposure to NewLink Genetics Corp. : December 27, 2016 Dec 27 2016
NewLink Genetics (NLNK) Jumps: Stock Adds 10% in Session Dec 27 2016
Shark Bites: We Knew Today Would Be Slow, but Come On… Dec 23 2016
Do Hedge Funds Love Western Asset Mortgage Capital Corp (WMC)? Dec 20 2016
ETFs with exposure to NewLink Genetics Corp. : December 16, 2016 Dec 16 2016
How Mercantile Bank Corp. (MBWM) Compares To Its Peers Dec 15 2016
NEWLINK GENETICS CORP Files SEC form 8-K/A, Termination of a Material Definitive Agreement Dec 13 2016
Hedge Funds Are Dumping Monarch Casino & Resort, Inc. (MCRI) Dec 10 2016
NEWLINK GENETICS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement Nov 29 2016
NewLink Genetics Corp. breached its 50 day moving average in a Bearish Manner : NLNK-US : November... Nov 22 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)